Stem Cell Stock Review Updates Coverage On Accurexa – KATV …

Posted: June 13, 2015 at 1:47 am

This article was originally distributed via SproutNews. SproutNews, WorldNow and this Site make no warranties or representations in connection therewith.

BEVERLY HILLS, CA / ACCESSWIRE / June 12, 2015 / The Stem Cell Stock Review has updated coverage on the company and will be providing ongoing coverage. Roland Rick Perry, Editor of the Review stated Accurexas end goal is to provide a medical device that can save lives not by improving the therapeutics or drugs used to treat neurological disorders including brain tumors, but rather by improving the delivery method and effectiveness of currently approved drugs used to treat the disorders using a flexible delivery catheter. Adding, The device called Branchpoint is designed to permit Clinicians to tailor therapeutic delivery and give physicians more precise control of the volume of therapeutics delivered and ensure that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. We are excited to update coverage as they progress towards their filing a 510k submission with the FDA.

Accurexas Branchpoint microinjection brain catheter can be described as a quantum leap and game changing advancement in the technology of delivering drugs and therapeutics, directly to the brain over the common syringe (or cannula), as depicted in the report. The device was recently subject of a cover story in Molecular Therapy(R) (MT) magazine, the official journal of the American Society for Gene & Cell Therapy. The report can be viewed at both the Stem Cell and Bioteck Stock Review websites.

Stem Cell Stock Review Website: http://www.stemcellstockreview.com/research-reports.html

The Biotech Stock Review Website: http://www.thebiotechstockreview.com

About The Stem Cell Stock Review

The Stem Stock Review website provides individual news feeds for each company on the Watch List, enabling investors to easily follow the entire group with a single visit. Each Friday we issue a weekly head-line wrap up of stem cell industry news via our free newsletter. Also included are links to third party industry expert websites and leading news sources such as the Life Sciences Report, Edison Research, Futurity, the Timmerman Report, Fierce Biotech, BioMed Reports, Science Daily and research reports from a broad spectrum of Wall Street sources.

The Stem Cell Stock Review additionally has a Flipboard powered magazine which archives a collection of stem cell industry related articles from over 100 sources and can be found here: Stem Cell Stock Review Magazine: https://flipboard.com/@institution73s6/stem-cell-stock-review-8oe7m025y.

The Stem Cell Stock Review additionally has an online Internet TV channel called Biotech Exec TV, which hosts interviews with industry and Wall Street experts.

Biotech Exec TV: http://www.biotechexectv.com/

Read more:
Stem Cell Stock Review Updates Coverage On Accurexa - KATV ...

Related Post